- Together with the Baker Institute, Rhythm identifies best five-biomarker combination that can target the various stages of lung cancer
- The company used a cohort of 70 healthy and cancerous patients
- It will now move towards a larger study
- The results could lead to these biomarkers being translated into a commercial treatment
- RHY shares are trading at 18 cents at 10:19 am AEDT
Rhythm Biosciences (RHY) has received positive preliminary data from the Baker Institute in regard to its lung cancer diagnostic test.
Rhythm reports successfully identifying a five-biomarker combination that can target the various stages of lung cancer.
A preliminary assessment of up to 17 biomarkers was performed on 71 healthy volunteers and 70 lung cancer patients.
Shares, however, remained flat in the second hour of trade.
Results better than expected
Originally for research only, these biomarkers have proven they can distinguish between healthy and cancerous controls.
Rhythm has stated the results require further analysis through a larger cohort to justify continuing the project.
This it expects to support the case for further investment to advance all clinical possibilities.
The value of detecting lung cancer is obvious enough, but especially pertinent given that most patients report with symptoms too late.
Leading cause of cancer death
“These encouraging results warrant confirmation in a larger population and justify the continuation and advancement of the project,” Rhythm Biosciences wrote on Friday.
“Lung cancer remains the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure.
“The Australian Institute of Health and Welfare estimated that in 2022, 14,529 Australians were diagnosed with lung cancer, and more than 8,6064 died from the disease.”
RHY shares were trading at 18 cents at 10:19 am AEDT.